Halozyme Therapeutics, Inc. (NASDAQ:HALO – Get Rating) – Analysts at Zacks Research dropped their Q3 2022 EPS estimates for shares of Halozyme Therapeutics in a report released on Monday, September 19th. Zacks Research analyst I. Bandyopadhyay now expects that the biopharmaceutical company will post earnings of $0.51 per share for the quarter, down from their prior estimate of $0.56. The consensus estimate for Halozyme Therapeutics’ current full-year earnings is $1.92 per share.
A number of other research firms also recently commented on HALO. Morgan Stanley started coverage on shares of Halozyme Therapeutics in a report on Friday, September 9th. They issued an “overweight” rating and a $50.00 target price on the stock. The Goldman Sachs Group boosted their target price on shares of Halozyme Therapeutics from $48.00 to $60.00 and gave the stock a “buy” rating in a report on Thursday, May 26th. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $52.00.
Halozyme Therapeutics Stock Down 1.2 %
Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last released its quarterly earnings results on Tuesday, August 9th. The biopharmaceutical company reported $0.53 EPS for the quarter, topping analysts’ consensus estimates of $0.47 by $0.06. Halozyme Therapeutics had a net margin of 75.11% and a return on equity of 101.73%. The company had revenue of $152.37 million for the quarter, compared to the consensus estimate of $156.00 million. During the same period in the previous year, the firm earned $0.63 EPS. Halozyme Therapeutics’s revenue was up 11.7% on a year-over-year basis.
Institutional Inflows and Outflows
Institutional investors have recently made changes to their positions in the company. Snyder Capital Management L P increased its position in shares of Halozyme Therapeutics by 18.6% in the fourth quarter. Snyder Capital Management L P now owns 4,064,779 shares of the biopharmaceutical company’s stock worth $163,445,000 after acquiring an additional 637,303 shares in the last quarter. Royce & Associates LP acquired a new position in Halozyme Therapeutics in the 1st quarter valued at approximately $1,276,000. AMI Asset Management Corp increased its stake in Halozyme Therapeutics by 5.1% in the 1st quarter. AMI Asset Management Corp now owns 248,461 shares of the biopharmaceutical company’s stock valued at $9,909,000 after buying an additional 12,160 shares during the period. Gotham Asset Management LLC increased its stake in Halozyme Therapeutics by 92.6% in the 4th quarter. Gotham Asset Management LLC now owns 45,133 shares of the biopharmaceutical company’s stock valued at $1,815,000 after buying an additional 21,698 shares during the period. Finally, E Fund Management Co. Ltd. increased its stake in Halozyme Therapeutics by 53.7% in the 1st quarter. E Fund Management Co. Ltd. now owns 7,726 shares of the biopharmaceutical company’s stock valued at $308,000 after buying an additional 2,699 shares during the period. 91.72% of the stock is owned by hedge funds and other institutional investors.
About Halozyme Therapeutics
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- The Institutions Hold On To Darden Restaurants International
- What Steelcase’s Earnings Say About the Return to the Office?
- Is The Golden Age Of Homebuilding Already Over?
- These 3 Big Dividend Payers Also Boast Strong Price Growth
- Natural Gas Prices Continue To Rally, These Stocks Should Benefit
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.